The Expression Patterns of Immune Checkpoint Molecules in Colorectal Cancer: An Analysis Based on Microsatellite Status

• Published in: Biomedicines Vol. 12; no. 4; p. 752
• Main Authors: An, Sanghyun, Li, Wanlu, Do, Hyejin, Kwon, Hye Youn, Kim, Bora, Kim, Kwangmin, Kim, Youngwan, Cho, Mee-Yon
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.04.2024
• Subjects: Analysis; Antigens; Apoptosis; Cancer; Cancer therapies; Care and treatment; CD223 antigen; Cell activation; Cell death; Colorectal cancer; Colorectal carcinoma; colorectal neoplasms; Development and progression; Genes; Genetic aspects; Hospitals; Immune checkpoint; immune checkpoint proteins; Immunotherapy; Lymphocytes; Lymphocytes T; Medical equipment and supplies industry; Medical research; Medical test kit industry; Medicine, Experimental; Metastases; Metastasis; Microsatellite instability; Monoclonal antibodies; Patients; PD-1 protein; PD-L1 protein; T cells; Tumors; United States; South Korea; United States > US; microsatellite instability; immune checkpoint proteins; colorectal neoplasms; immunotherapy
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12040752

Recently, immunotherapy has arisen as a novel treatment approach for patients with colorectal cancer (CRC), but the effectiveness of immunotherapy varies in these patients. We hypothesized that immune checkpoint molecules (ICMs), which are the targets of immunotherapy, are often exhibited concomitantly. Our objective was to investigate the patterns of ICM expression in patients with CRC and the differences in ICM expression based on microsatellite instability status. The immunohistochemical expression of programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), and lymphocyte-activation gene 3 (LAG-3) in the tumor center and periphery was assessed in patients with non-metastatic colorectal cancer. We enrolled 83 patients with CRC: a total of 40 microsatellite-stable (MSS) and 43 microsatellite-instability-high (MSI-H) cancer patients. PD-L1 was more frequently expressed in the tumor center in the MSI-H patients with than that in the MSS patients (18 [41.9%] vs. 3 [7.5%], respectively; < 0.001), and the same trend was observed for TIM-3 expression (30 [69.8%] vs. 19 [47.5%], respectively; = 0.047). The concomitant expression of two or more ICMs was more frequently observed than no expression or the expression of a single molecule in both the MSS and MSI-H groups; a total of 34 (79.7%) patients with MSI-H cancer and 23 (57.5%) with MSS cancer showed ICM expression at the tumor center, whereas 34 (79.7%) patients with MSI-H cancer and 22 (55%) with MSS cancer showed expression at the tumor periphery. Patients with the genetic characteristics of MSI-H cancer showed higher expression levels of ICMs than those in patients with MSS cancer, and predominantly, two or more ICMs were concurrently expressed. Our findings highlight the potential efficacy of the dual-blockade approach in immunotherapy, particularly in patients with MSI-H CRC.